In routine setting, interdisciplinary teams satisfactorily manage extravasations

Share this content:

the ONA take:

In a routine setting, the standardized management of cytotoxic extravasations of antitumoral compounds by an interdisciplinary task force resulted in a satisfactory outcome, a study published in the journal Supportive Care in Cancer has shown.

For the study, researchers sought to assess extravasations of antitumoral compounds and the efficacy of its structured interdisciplinary managements in a routine setting. Researchers longitudinally observed 169 patients who were managed for cytotoxic extravasation according to a prospective approach. Patients underwent surgery if conservative measures failed.

Results showed that conservative management was successful in 91.7% of patients. Researchers found that extravasations of anthracyclines (i.e., doxorubicin), platinum compounds (i.e., cisplatin), vinca alkaloids (i.e., vincristine), and taxanes (i.e., paclitaxel) were associated with erythema, edema, and pain.

The median duration until full resolution of symptoms was 55 days for anthracyclines, 27 days for taxanes and vinca alkaloids, and 14 days for platinum compounds, with statistical significance between the vesicants.

The findings suggest that "the proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment."

For 80% of colorectal cancers, Janus kinase (JAK) inhibitors may be effective
In a routine setting, the standardized management of cytotoxic extravasations resulted in a satisfactory outcome.
In a longitudinal observation, extravasation of antitumoural compounds and the efficacy of its structured interdisciplinary management were assessed in a routine setting.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs